

RESULTS OF ANNUAL GENERAL MEETING

Melbourne, Australia – 7 October 2026: Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the results of today’s Annual General Meeting of shareholders.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the Annual General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the Annual General Meeting.

All resolutions to be voted on at the meeting were decided on a poll.

The Board thanks shareholders for their attendance and participation at the 2026 Annual General Meeting.

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated, and Percheron aims to commence further clinical trials in CY2026.

For further information, please see our website at www.PercheronTx.com, or email info@PercheronTx.com.

This announcement has been authorised for release to the Australian Securities Exchange by the Board of Directors.

Percheron Therapeutics Limited
Annual General Meeting
Wednesday, 07 October 2026
Results of Meeting



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. To Adopt the 2026 Remuneration Report	Ordinary	206,896,580 96.19%	2,665,799 1.24%	5,531,903 2.57%	250	212,428,483 98.76%	2,665,799 1.24%	250	Carried	N/A
2. Election of Director - Dr James Garner	Ordinary	282,694,179 97.44%	1,895,617 0.65%	5,531,903 1.91%	525,333	288,226,082 99.35%	1,895,617 0.65%	525,333	Carried	N/A
3. Approval for issue of Restricted Stock Units to Dr Michael Baker	Ordinary	206,571,390 96.04%	4,491,265 2.09%	4,031,877 1.87%	0	210,603,267 97.91%	4,491,265 2.09%	0	Carried	N/A
4. Ratification of Prior Issue of Adviser Options to Blue Ocean	Ordinary	282,742,890 97.28%	3,872,265 1.33%	4,031,877 1.39%	0	286,774,767 98.67%	3,872,265 1.33%	0	Carried	N/A
5. Ratification of Prior Issue of Joint Lead Manager Options to Blue Ocean and Cygnet Capital	Ordinary	282,727,890 97.28%	3,887,265 1.34%	4,031,877 1.39%	0	286,759,767 98.66%	3,887,265 1.34%	0	Carried	N/A
6. Re-approval of Percheron Therapeutics Employee Share Option Plan	Ordinary	206,892,830 96.86%	2,569,799 1.20%	4,131,877 1.93%	2,152,526	211,024,707 98.80%	2,569,799 1.20%	2,152,526	Carried	N/A
7. Approval of potential termination benefits under the ESOP	Ordinary	206,348,593 96.61%	3,114,036 1.46%	4,131,877 1.93%	2,152,526	210,330,470 98.54%	3,114,036 1.46%	2,152,526	Carried	N/A
8. Approval of 10% Placement Capacity (Special Resolution)	Special	282,100,104 97.06%	4,105,265 1.41%	4,441,663 1.53%	0	286,541,767 98.59%	4,105,265 1.41%	0	Carried	N/A
9(a). Ratification of prior issue of Tranche 1 Placement Shares issued under Listing Rule 7.1	Ordinary	282,115,104 97.08%	4,052,765 1.39%	4,441,663 1.53%	37,500	286,556,767 98.61%	4,052,765 1.39%	37,500	Carried	N/A

9(b). Ratification of prior issue of Tranche 1 Placement Shares issued under Listing Rule 7.1A	Ordinary	282,115,104 97.08%	4,052,765 1.39%	4,441,663 1.53%	37,500	286,556,767 98.61%	4,052,765 1.39%	37,500	Carried	N/A
10. Approval for issue of Tranche 2 Placement Shares	Ordinary	282,100,104 97.06%	4,105,265 1.41%	4,441,663 1.53%	0	286,541,767 98.59%	4,105,265 1.41%	0	Carried	N/A
11. Approval for issue of Placement Options	Ordinary	281,742,658 96.94%	4,105,265 1.41%	4,799,109 1.65%	0	286,541,767 98.59%	4,105,265 1.41%	0	Carried	N/A
12(a). Approval for issue of Related Party Placement Securities to Dr Michael Baker	Ordinary	284,469,652 98.00%	4,105,265 1.41%	1,714,669 0.59%	357,446	286,184,321 98.59%	4,105,265 1.41%	357,446	Carried	N/A
12(b). Approval for issue of Related Party Placement Securities to Mr James Baker	Ordinary	284,444,319 98.06%	4,105,265 1.42%	1,514,669 0.52%	582,779	285,958,988 98.58%	4,105,265 1.42%	582,779	Carried	N/A
13. Approval of Issue of Broker Options to Blue Ocean and Cygnet Capital	Ordinary	282,099,854 97.06%	4,105,265 1.41%	4,441,663 1.53%	250	286,541,517 98.59%	4,105,265 1.41%	250	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.